Early nutritional screening may benefit patients receiving vismodegib
the ONA take:
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib, a new study published online ahead of print in the journal Supportive Care in Cancer has suggested.
Although vismodegib is effective in the treatment of this type of skin cancer, weight loss and dysgeusia (persistent abnormal taste or change in taste) are common treatment-related adverse events.
Therefore, researchers sought to monitor the nutritional status of vismodegib-treated patients, as well as assess the incidence of dysgeusia and the benefit of early nutritional management.
For the prospective study, researchers enrolled 45 patients with locally advanced or metastatic basal cell carcinoma who started vismodegib between October 2011 and May 2013 at Nantes University Hospital in France.
Of those, 24 patients had not received any specific nutritional management while 21 patients were evaluated by a physician from the Nutrition Support Unit and received dietary counseling at the time of vismodegib initiation.
Results showed that 24% of patients receiving dietary counseling were undernourished at vismodegib initiation and the 6-month cumulative incidence of dysgeusia was 71%.
Researchers found that 38% of patients receiving dietary counseling experienced a weight loss greater than 5% compared with 54% of those who did not receive any specific nutritional management.
“The potential benefit of nutritional support in this setting warrants further investigation,” the authors conclude.
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|